September 2, 2020

New Drug Combination May Slow Symptom Course Early on in ALS

Positive clinical trial points to a possible additional option for patients with ALS. Dr. Stephen Goutman explains the excitement and the caution.

from the M Health Lab Blog by Haley Otman

Michigan Medicine Lab Blog Logo

 

 

  

  

A new drug combination could help slow the effects of amyotrophic lateral sclerosis, or ALS, on patients’ day-to-day ability to function, such as eating independently, walking and speaking. 

Dr. Stephen Goutman
Dr. Stephen Goutman

“ALS is a disease where the motor neuron cells die, and the hope with this drug is, if given early, it may slow the death of these motor neuron cells that lead to weakness and progression of ALS,” says Stephen Goutman, M.D., director of the Michigan Medicine Pranger ALS Clinic and one of the researchers who led a trial site for the drug.

ALS, also known as Lou Gehrig’s disease, is fatal, so any new treatments offer hope for those living with the disease.

“This is an exciting study and I’m glad we could allow our patients at the Pranger ALS Clinic to participate,” Goutman says. “However, the need for a cure still exists and we remain committed to continuing this work.”

 Read More

Stephen Goutman, MD, photo

Stephen Goutman, MD, MS

Director, Pranger ALS Clinic
Associate Director, ALS Center of Excellence
Associate Professor of Neurology
Department of Neurology
5017 BSRB
Ann Arbor MI 48109-2200
Pathogenesis and Drug Discovery for ALS